Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

PHASE1RecruitingINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

BAT8006 for Injection

Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Trial Locations (17)

Unknown

RECRUITING

Anhui Cancer Hospital, Hefei

NOT_YET_RECRUITING

Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing

RECRUITING

Fujian Cancer Hospital, Fuzhou

RECRUITING

Sun Yat-Sen Memorlal Hospital, Sun Yat-Sen University, Guangzhou

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen

RECRUITING

Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute, Nanning

RECRUITING

Hubei Cancer Hospital, Wuhan

RECRUITING

Tongji Hospital, Tongji Medical College of Hust, Wuhan

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

The First Hospital of Jilin University, Changchun

NOT_YET_RECRUITING

Liaoning Cancer Hospital&Institute, Shenyang

RECRUITING

Shandong Cancer Hospital, Jinan

NOT_YET_RECRUITING

Shanxi Provincial Cancer Hospital, Taiyuan

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY